CooperCompanies stock (US21664P1039): earnings update and growth drivers in eye care and fertility

CooperCompanies recently reported results for its fiscal second quarter of 2024 and highlighted continued growth in its CooperVision and CooperSurgical businesses, which span contact lenses and fertility-focused medical devices, according to a results release dated 05/30/2024 from the company’s website and coverage by Reuters as of 05/30/2024. The company also discussed demand trends in silicone hydrogel lenses and fertility solutions, which remain key revenue drivers for investors tracking the US healthcare and medical devices sector, according to the same company communication on 05/30/2024.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

CooperCompanies: core business model

CooperCompanies operates in two main segments: CooperVision, which develops and sells soft contact lenses, and CooperSurgical, which focuses on fertility, genomics and women’s health products, according to the company’s description in its fiscal 2023 Form 10-K filed with the US Securities and Exchange Commission on 12/21/2023 and information on its corporate site dated 2024. CooperVision is a significant player in the global soft contact lens market, offering lenses for myopia, hyperopia, astigmatism and presbyopia, while CooperSurgical provides equipment, consumables and services for fertility clinics and related specialties, based on the same filings.

Within CooperVision, the company emphasizes silicone hydrogel daily disposable lenses and toric lenses as higher-value categories, which has been a strategic focus over several reporting periods, according to management commentary included in the fiscal 2023 annual report published on 12/21/2023. These products generally command higher average selling prices compared with older hydrogel products, and the company has reported that mix shifts toward these premium lenses have been supportive for revenue growth and margins in recent years, according to the same SEC filing on 12/21/2023.

CooperSurgical’s portfolio covers fertility-related equipment used by in vitro fertilization (IVF) clinics, as well as genetic testing and women’s health products such as office and surgical devices, according to the fiscal 2023 Form 10-K published on 12/21/2023. The company has highlighted demographic trends and rising demand for fertility treatments as structural supports for its long-term growth outlook in this segment, particularly in developed markets including the United States, Europe and parts of Asia, based on the same report. While fertility cycles can be sensitive to economic conditions, management has noted that many procedures are considered important by patients and clinics, which can provide some resilience, as described in that filing.

From a business model perspective, CooperCompanies generates revenue primarily through recurring sales of consumables such as contact lenses, fertility media and laboratory supplies, alongside capital equipment and services sold to clinics and practitioners, according to the company’s annual disclosures as of 12/21/2023. Recurring product usage and replacement cycles in both eye care and fertility-related consumables contribute to a relatively stable revenue base when compared with sectors that depend mainly on one-off equipment purchases, based on the same 10-K report. This recurring component is particularly relevant for US investors seeking exposure to healthcare businesses with ongoing product replacement dynamics.

Main revenue and product drivers for CooperCompanies

In its fiscal second-quarter 2024 results release dated 05/30/2024, CooperCompanies reported that CooperVision continued to benefit from uptake of daily disposable silicone hydrogel lenses and specialty toric lenses, which management identified as key revenue growth drivers. While detailed segment numbers may vary by quarter, the company has repeatedly pointed to these premium categories as outgrowing the broader contact lens market, according to the same 05/30/2024 release and supporting commentary by CooperCompanies as of 05/30/2024. These lenses are targeted at both existing lens wearers shifting to newer modalities and new wearers entering the category, including in the US and other major markets.

For CooperSurgical, the company’s results commentary on 05/30/2024 discussed continued demand in fertility-related products and services, including laboratory equipment and consumables used by IVF clinics. The business also includes genetic testing offerings and women’s health products, which provide multiple revenue streams across different points of the fertility and reproductive health journey, according to CooperCompanies’ fiscal 2023 Form 10-K published on 12/21/2023. Management has indicated that clinics often require ongoing purchases of consumables and services, offering recurring revenue characteristics, although quarterly growth can be influenced by procedure volumes and clinic activity levels.

Product innovation is a central element of the company’s revenue strategy. CooperVision regularly launches or refreshes lens families to address visual conditions like astigmatism and presbyopia and to improve wearer comfort, often emphasizing oxygen permeability and wettability characteristics in its silicone hydrogel offerings, as described in the company’s product literature and fiscal 2023 annual filing dated 12/21/2023. CooperSurgical, meanwhile, invests in fertility technologies and lab systems that aim to improve workflow and outcomes for clinics, such as embryology lab equipment and media, according to the same SEC filing, which can help clinics standardize processes and potentially support demand for associated consumables over time.

Geographically, CooperCompanies generates a substantial portion of its revenue from North America, Europe and Asia-Pacific, with the United States being a key market for both CooperVision and CooperSurgical, based on the regional breakdowns included in the fiscal 2023 Form 10-K dated 12/21/2023. The company’s presence in the US eye care market provides exposure to a large base of contact lens wearers, while its fertility products are used by US fertility clinics and women’s health providers. For US investors, this geographic mix means that the performance of the domestic healthcare system, consumer spending dynamics and insurance frameworks can influence demand trends for the company’s products over time.

In addition to product and regional drivers, CooperCompanies has historically engaged in portfolio management through acquisitions and selective divestitures to refine its focus on core areas like specialty contact lenses and fertility solutions, according to the company’s transaction history discussed in its 2023 annual report filed on 12/21/2023. Integration of acquired businesses can provide incremental scale and broaden the product range, although it can also bring integration costs and operational complexity. The company typically describes synergy opportunities and integration progress in its quarterly and annual disclosures, offering investors a window into how such deals contribute to revenue and earnings over time.

Conclusion

CooperCompanies occupies a focused position in the global eye care and fertility markets through its CooperVision and CooperSurgical segments, with a business model that emphasizes recurring sales of consumables and premium products, according to its fiscal 2023 Form 10-K dated 12/21/2023 and the fiscal second-quarter 2024 results release on 05/30/2024. Recent quarterly reporting points to ongoing growth in high-value contact lenses and continued demand for fertility-related equipment and supplies, although performance can vary by segment and region. For US investors, the stock offers exposure to structural trends in vision correction and fertility treatment usage, set against broader considerations such as competition, regulatory factors and execution on product innovation and integration. As with any healthcare-related equity, potential investors may wish to monitor upcoming earnings releases, regulatory developments and market dynamics in both the eye care and fertility sectors when assessing the company’s future prospects.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.